Sirna Granted Two UK Patents

The UK Patent Office recently granted Sirna Therapeutics two broad patents that cover short interfering RNAs, and the company has similar patents pending in the US Patent and Trademark Office and the European Patent Office.

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The UK Patent Office recently granted Sirna Therapeutics two broad patents that cover short interfering RNAs, and the company has similar patents pending in the US Patent and Trademark Office and the European Patent Office.

The patents lock up the use of short interfering RNAs (siRNAs) as therapeutics in the UK market, according to Sirna, but some say the company's intellectual property position is not that strong. Sirna Therapeutics, which is in the process of moving from Boulder, Colo., to San Francisco, changed its name from Ribozyme Pharmaceuticals in 2003 and has been publicly traded for several years. The company, which has roughly 80 employees, now specializes in developing RNA interference (RNAi)-based therapies for macular degeneration, hepatitis C, and Huntington disease, among other ailments. The company has filed for patents on hundreds of applications for siRNAs.

The first patent (UK patent No. 2397818) broadly covers any chemical modifications that alter ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Edward Winnick

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio